[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597200":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":50,"collaborators":52,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":20,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Fujian Cancer Hospital","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Study group : iparomlimab and tuvonralimab plus nab-paclitaxel, cisplatin","EXPERIMENTAL","Participants will receive iparomlimab and tuvonralimab at a dose of 5 mg\u002Fkg, nab-paclitaxel at 260 mg\u002Fm², and cisplatin at 75-80 mg\u002Fm², all administered intravenously on day 1. After three weeks, participants will continue with only iparomlimab and tuvonralimab(5 mg\u002Fkg) for two additional cycles at an interval of 3 weeks.",[13],"Drug: neoadjuvant chemo-immunotherapy: Iparomlimab and tuvonralimab plus cisplatin,nab-paclitaxel for 1 cycle and Iparomlimab and tuvonralimab for 2 cycles",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","neoadjuvant chemo-immunotherapy: Iparomlimab and tuvonralimab plus cisplatin,nab-paclitaxel for 1 cycle and Iparomlimab and tuvonralimab for 2 cycles","Neoadjuvant chemo-immunotherapy: Iparomlimab and tuvonralimab, cisplatin, and nab-paclitaxel for 1 cycle, then Iparomlimab and tuvonralimab continued for 2 cycles at 3-week intervals. Details:\n\nIparomlimab and tuvonralimab 5 mg\u002Fkg, IV infusion, Q3W for 3 cycles Cisplatin：75-80 mg\u002Fm2, IV infusion, (cycle 1) Nab-paclitaxel 260 mg\u002Fm2，30min，IV infusion,(cycle 1)",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Yang Sun, PHD","CONTACT","86-15959028989","sunyang@fjzlhospital.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Jie Lin, MD","86-15860818601","linjie@fjzlhospital.com",[32],{"facility":5,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Fuzhou","Fujian","350014","China","CN",{"type":40,"coordinates":41},"Point",[42,43],119.30611,26.06139,{"lat":43,"lon":42},[46,48],{"name":23,"role":24,"phone":47,"phoneExt":20,"email":26},"86+15959028989",{"name":23,"role":49,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"type":51,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[53,56,58],{"name":54,"class":55},"Jiangsu Cancer Institute & Hospital","OTHER",{"name":57,"class":55},"Fuzhou University Affiliated Provincial Hospital",{"name":59,"class":55},"First Affiliated Hospital of Fujian Medical University","100597200","phase-2-neoadjuvant-iparomlimab-and-tuvonralimab-plus-chemotherapy-eclipse-for-locally-advanced-cervical-cancer-nice-cc-100597200",false,"NCT07055399","Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)","Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Chemotherapy-eclipse for Locally Advanced Cervical Cancer：A Single-arm, Open-label, Phase II Trial","NICE-CC","Inclusion Criteria:\n\n* 1、Written informed consent\n* 2、18-70 years old\n* 3、Adequate organ function and ECOG of 0 \\~1\n* 4、Without systemic therapy at the time of enrollment\n* 5、FIGO 2018 stage IB3, IIA2, or IIIC1r\n* 6、Histologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix\n* 7、Measurable lesions could be defined by RECIST v1.1\n* 8、Willing to get blood\u002F tumor tissue tested\n* 9、Patients who observed the rules about the scheduled visit, study schedule, and medical examination\n* 10、The function of major organs is normal, and the following criteria are met:\n* 10.1 Blood routine examination must meet: (no blood transfusion within 14 days)\n\nHb≥90g\u002FL:\n\nANC≥1.5x10\\^9\u002FL; PLT≥100x10\\^9\u002FL;\n\n* 10.2 The biochemical examination must meet the following standards BIL \\\u003C 1.5 × ULN; ALT and AST \\\u003C 2.5xULN; ALB≥ 28 g\u002FL\n* 11、Patients who are willing and able to comply with visiting arrangements, treatment plans, laboratory tests, and other research procedures.\n\nExclusion Criteria:\n\n* 1、History of other malignancies within 3 years\n* 2、Participate in other clinical trials at the same time\n* 3、Active autoimmune disease, which needs systemic therapy\n* 4、Uncontrolled infection, which needs systemic therapy\n* 5、History of allogeneic tissue\u002Fsolid organ transplant\n* 6、Serious illness, such as severe mental disorders, cardiac disease, coagulation disorders, digestive system disease, etc\n* 7、Active HBV, HCV, or HIV infection\n* 8、Pregnant or lactating female patients\n* 9、Drug or alcohol abuse\n* 10、 Unable or unwilling to sign the informed consent","FEMALE","18 Years","70 Years",{"count":72,"type":73},43,"ESTIMATED","INTERVENTIONAL",[76],"PHASE2","Locally advanced cervical cancer (LACC) remains a significant global health concern with limited treatment options. Recent advancements suggest that using neoadjuvant anti-PD-1 inhibitors in combination with chemotherapy, followed by radical surgery, may be an effective treatment strategy for patients with PD-L1-positive LACC. This study aims to evaluate the efficacy and safety of preoperative treatment with iparomlimab and tuvonralimab-a bifunctional PD-1\u002FCTLA-4 dual blocker-combined with chemotherapy for LACC.",[79],"Locally Advanced Cervical Cancer",[81,82,83,84],"Cervical Cancer","neoadjuvant","chemo-immunotherapy","iparomlimab and tuvonralimab;","2025-09-05",{"date":87,"type":88},"2025-09-11","ACTUAL",{"date":90,"type":88},"2025-08-21",{"date":92,"type":73},"2029-09-01",{"name":5,"class":6},1]